Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novoste Beta-Cath

This article was originally published in The Gray Sheet

Executive Summary

Smaller 3.5 Fr version of the intravascular brachytherapy catheter gains PMA supplement approval, announced Feb. 13. The smallest diameter catheter commercially available, the device can be used with a 6 Fr guiding catheter, the firm says. The system will allow treatment of restenosis in vessels too small for the current 5 Fr system. Both are available with 30 mm and 40 mm radioactive source trains. The Beta-Cath is installed in 340 U.S. hospitals and controls about 85% of the U.S. brachytherapy market (1"The Gray Sheet" Feb. 4, 2002, p. 17)...

You may also be interested in...


Vascular brachytherapy device maker launches a third radiation source train for its Beta-Cath vascular radiation delivery system, the 60 mm in length, based on results of a 139-patient subset from the 1,098 patient RENO European registry. In this subset, the Beta-Cath reduced target vessel revascularization 75% versus the placebo group in the 94-patient LONG WRIST study. Average lesion length was 35.3 mm in RENO and 28 mm in LONG WRIST. Source trains of 30 mm and 40 mm also are available, in 5 Fr and 3.5 Fr diameters (1"The Gray Sheet" Feb. 18, 2002, In Brief)...

Novoste Holding Line Against Guidant In Coronary Brachytherapy Market

Novoste says its recall of 50 Beta-Cath brachytherapy transfer units due to incorrect calibration will contribute to a modest sales decline during the current quarter versus the fourth quarter of 2001

Biden Extends Helping Hand To Small US Manufacturers, Vendors With ‘Made In America’ EO

The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts